Literature DB >> 22250078

Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.

Jason J Schwartz1, Lisa Pappas, Heather F Thiesset, Gabriela Vargas, John B Sorensen, Robin D Kim, William R Hutson, Kenneth Boucher, Terry Box.   

Abstract

Current liver allocation policy in the United States grants liver transplant candidates with stage T2 hepatocellular carcinoma (HCC) a priority Model for End-Stage Liver Disease (MELD) score of 22, regardless of age. Because advanced age may portend an increase in all-cause mortality after transplantation for any diagnosis, the aim of this study was to examine overall posttransplant survival in elderly patients with HCC versus younger cohorts. Based on Organ Procurement and Transplantation Network data, Kaplan-Meier 5-year survival rates were compared. Recipients undergoing primary liver transplantation were stratified into cohorts based on age (<70 or ≥ 70 years) and the receipt of MELD exception points for HCC. Log-rank and Wilcoxon tests were used for statistical comparisons. In 2009, 143 transplants were performed for patients who were 70 years old or older. Forty-two percent of these patients received a MELD exception for HCC. Regardless of the diagnosis, the overall survival rate was significantly attenuated for the septuagenarians versus the younger cohort. After 5 years of follow-up, this disparity exceeded 10% to 15% depending on the populations being compared. The 1-, 2-, 3-, 4-, and 5-year actuarial survival rates were 88.4%, 83.2%, 79.6%, 76.1%, and 72.7%, respectively, for the patients who were younger than 70 years and 81.1%, 73.8%, 67.1%, 61.9%, and 55.2%, respectively, for the patients who were 70 years old or older. Five-year survival was negatively affected for patients with HCC who were younger than 70 years; this disparity was not observed for patients with HCC who were 70 years old or older. In conclusion, although patients who are 70 years old or older compose a small fraction of transplant recipients in the United States, patients in this group undergoing transplantation for HCC form an even smaller subset. Overall, transplantation in this age group yields outcomes inferior to those for younger cohorts. However, unlike patients who are less than 70 years old and receive MELD exception points, overall liver transplant survival is not affected by HCC at an advanced age.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22250078     DOI: 10.1002/lt.23385

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  15 in total

Review 1.  CON: Patients of Advanced Age Should Not Routinely Undergo Liver Transplantation.

Authors:  Avash Kalra; Michael Kriss; Prashanth Francis; J P Norvell
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-09-02

2.  Functional impairment in older liver transplantation candidates: From the functional assessment in liver transplantation study.

Authors:  Connie W Wang; Kenneth E Covinsky; Sandy Feng; Hilary Hayssen; Dorry L Segev; Jennifer C Lai
Journal:  Liver Transpl       Date:  2015-11-06       Impact factor: 5.799

3.  Is liver transplantation safe and effective in elderly (≥70 years) recipients? A case-controlled analysis.

Authors:  Gregory C Wilson; R Cutler Quillin; Koffi Wima; Jeffrey M Sutton; Richard S Hoehn; Dennis J Hanseman; Ian M Paquette; Flavio Paterno; E Steve Woodle; Daniel E Abbott; Shimul A Shah
Journal:  HPB (Oxford)       Date:  2014-08-06       Impact factor: 3.647

4.  Use of Population-based Data to Demonstrate How Waitlist-based Metrics Overestimate Geographic Disparities in Access to Liver Transplant Care.

Authors:  D S Goldberg; B French; G Sahota; A E Wallace; J D Lewis; S D Halpern
Journal:  Am J Transplant       Date:  2016-05-17       Impact factor: 8.086

Review 5.  Defining the threshold for too sick for transplant.

Authors:  Jennifer C Lai
Journal:  Curr Opin Organ Transplant       Date:  2016-04       Impact factor: 2.640

6.  Evolving Role of Liver Transplantation in Elderly Recipients.

Authors:  Omar Y Mousa; Justin H Nguyen; Yaohua Ma; Bhupendra Rawal; Kaitlyn R Musto; Marjorie K Dougherty; Jefree A Shalev; Denise M Harnois
Journal:  Liver Transpl       Date:  2019-07-20       Impact factor: 5.799

7.  Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-Hepatocellular Carcinoma Factors.

Authors:  Nia Adeniji; Vinodhini Arjunan; Vijay Prabhakar; Ajitha Mannalithara; Tara Ghaziani; Aijaz Ahmed; Paul Kwo; Mindie Nguyen; Marc L Melcher; Ronald W Busuttil; Sander S Florman; Brandy Haydel; Richard M Ruiz; Goran B Klintmalm; David D Lee; C Burcin Taner; Maarouf A Hoteit; Elizabeth C Verna; Karim J Halazun; Amit D Tevar; Abhinav Humar; William C Chapman; Neeta Vachharajani; Federico Aucejo; Trevor L Nydam; James F Markmann; Constance Mobley; Mark Ghobrial; Alan N Langnas; Carol A Carney; Jennifer Berumen; Gabriel T Schnickel; Debra L Sudan; Johnny C Hong; Abbas Rana; Christopher M Jones; Thomas M Fishbein; Vatche Agopian; Renumathy Dhanasekaran
Journal:  Liver Transpl       Date:  2021-03-01       Impact factor: 5.799

8.  Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic Kidney Disease: Is There an Appropriate Upper Age Cutoff?

Authors:  David S Goldberg; Rodrigo M Vianna; Eric Fleming Martin; Paul Martin; Leopoldo Ramon Arosemena Benitez; Christopher Blackburn O'Brien; Kalyan R Bhamidimarri
Journal:  Transplantation       Date:  2020-12       Impact factor: 4.939

9.  Living Donor Liver Transplant in Patients Aged 60 Years or Older: Experience from a Large Volume Centre in India.

Authors:  Ravindra Nidoni; Rajasekhar Kandagaddala; Shaleen Agarwal; Rajesh Dey; Bhargava R Chikkala; Subhash Gupta
Journal:  J Clin Exp Hepatol       Date:  2020-07-18

10.  Outcomes Between Elderly and Young Hepatocellular Carcinoma Living Donor Liver Transplantation Recipients: A Single-Center Experience.

Authors:  Hong Yu Li; Yong Gang Wei; Lv Nan Yan; Bo Li
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.